RESULTS
DISEASE PROGRESSION
Sixteen patients were enrolled between December 2016 and December 2018, at six centers. Their median age was 52.4 years, with 56% being males (Table Patient baseline demographics.One patient was ineligible and did not receive treatment. Although 15 patients started Cycle 1 of treatment, 4 received <40% of the expected Cycle 1 sapanisertib dosing and 11 received >40% of the expected Cycle 1 dosing. Three of these 15 patients received 4 or fewer days of sapanisertib. The median duration of sapanisertib treatment was 16 days (range 0–64), and only 3 patients received any Cycle 2 of treatment. Reasons patients went off study after receiving <28 days of sapanisertib include disease progression (